CO2017009404A2 - Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario - Google Patents
Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditarioInfo
- Publication number
- CO2017009404A2 CO2017009404A2 CONC2017/0009404A CO2017009404A CO2017009404A2 CO 2017009404 A2 CO2017009404 A2 CO 2017009404A2 CO 2017009404 A CO2017009404 A CO 2017009404A CO 2017009404 A2 CO2017009404 A2 CO 2017009404A2
- Authority
- CO
- Colombia
- Prior art keywords
- hereditary angioedema
- attack
- prevent
- plasma kallikrein
- kallikrein inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140277P | 2015-03-30 | 2015-03-30 | |
| US201562140289P | 2015-03-30 | 2015-03-30 | |
| US201562214293P | 2015-09-04 | 2015-09-04 | |
| PCT/US2016/024921 WO2016160926A1 (en) | 2015-03-30 | 2016-03-30 | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009404A2 true CO2017009404A2 (es) | 2018-03-09 |
Family
ID=57005262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009404A CO2017009404A2 (es) | 2015-03-30 | 2017-09-15 | Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180298110A1 (enExample) |
| EP (2) | EP3916020A1 (enExample) |
| JP (3) | JP7008920B2 (enExample) |
| KR (3) | KR20250057946A (enExample) |
| CN (1) | CN107614532A (enExample) |
| AU (2) | AU2016243160B2 (enExample) |
| BR (1) | BR112017020864A2 (enExample) |
| CA (1) | CA2979713A1 (enExample) |
| CO (1) | CO2017009404A2 (enExample) |
| EA (1) | EA201792161A1 (enExample) |
| HK (1) | HK1250995A1 (enExample) |
| IL (2) | IL254292B1 (enExample) |
| MX (2) | MX2017012423A (enExample) |
| WO (1) | WO2016160926A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011917A1 (en) | 2010-01-06 | 2022-06-15 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| KR20230109785A (ko) | 2014-03-27 | 2023-07-20 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
| IL311156A (en) * | 2015-12-11 | 2024-04-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| KR20250030022A (ko) | 2016-09-16 | 2025-03-05 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커 |
| EP4494698A3 (en) | 2017-08-04 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Inhibitors of plasma kallikrein and uses thereof |
| WO2019166874A1 (en) * | 2018-02-28 | 2019-09-06 | Lifesci Pharmaceuticals, Inc. | Treatment of hereditary angioedema |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| JP7585193B2 (ja) * | 2018-08-30 | 2024-11-18 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| ATE477020T1 (de) | 2002-06-07 | 2010-08-15 | Dyax Corp | Prevention und verringerung von ischemia |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| EP4011917A1 (en) * | 2010-01-06 | 2022-06-15 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| AU2012204202A1 (en) * | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| AU2012250872B2 (en) | 2011-05-02 | 2017-07-13 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| IL273688B2 (en) * | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| EP3594244A1 (en) * | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EP3808857B1 (en) | 2013-10-21 | 2025-12-10 | Takeda Pharmaceutical Company Limited | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
-
2016
- 2016-03-30 BR BR112017020864-4A patent/BR112017020864A2/en not_active Application Discontinuation
- 2016-03-30 CN CN201680018200.7A patent/CN107614532A/zh active Pending
- 2016-03-30 KR KR1020257012913A patent/KR20250057946A/ko active Pending
- 2016-03-30 MX MX2017012423A patent/MX2017012423A/es unknown
- 2016-03-30 EP EP21167802.4A patent/EP3916020A1/en active Pending
- 2016-03-30 HK HK18110329.1A patent/HK1250995A1/zh unknown
- 2016-03-30 WO PCT/US2016/024921 patent/WO2016160926A1/en not_active Ceased
- 2016-03-30 IL IL254292A patent/IL254292B1/en unknown
- 2016-03-30 KR KR1020177031279A patent/KR102607829B1/ko active Active
- 2016-03-30 AU AU2016243160A patent/AU2016243160B2/en active Active
- 2016-03-30 CA CA2979713A patent/CA2979713A1/en active Pending
- 2016-03-30 EA EA201792161A patent/EA201792161A1/ru unknown
- 2016-03-30 EP EP16774069.5A patent/EP3286226A4/en not_active Withdrawn
- 2016-03-30 IL IL305207A patent/IL305207A/en unknown
- 2016-03-30 KR KR1020237040648A patent/KR102799778B1/ko active Active
- 2016-03-30 US US15/562,671 patent/US20180298110A1/en not_active Abandoned
- 2016-03-30 JP JP2017549388A patent/JP7008920B2/ja active Active
-
2017
- 2017-09-15 CO CONC2017/0009404A patent/CO2017009404A2/es unknown
- 2017-09-27 MX MX2023010206A patent/MX2023010206A/es unknown
-
2021
- 2021-10-13 US US17/500,214 patent/US20220169749A1/en active Pending
- 2021-12-16 JP JP2021204200A patent/JP7309836B2/ja active Active
-
2022
- 2022-05-12 AU AU2022203180A patent/AU2022203180B2/en active Active
-
2023
- 2023-07-05 JP JP2023110592A patent/JP2023130442A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220169749A1 (en) | 2022-06-02 |
| KR20230164767A (ko) | 2023-12-04 |
| AU2016243160B2 (en) | 2022-02-24 |
| BR112017020864A2 (en) | 2018-07-10 |
| EA201792161A1 (ru) | 2018-04-30 |
| WO2016160926A1 (en) | 2016-10-06 |
| JP7008920B2 (ja) | 2022-01-25 |
| EP3286226A1 (en) | 2018-02-28 |
| EP3916020A1 (en) | 2021-12-01 |
| CN107614532A (zh) | 2018-01-19 |
| NZ774543A (en) | 2024-04-26 |
| EP3286226A4 (en) | 2018-12-05 |
| MX2017012423A (es) | 2018-01-26 |
| IL254292B1 (en) | 2025-09-01 |
| IL305207A (en) | 2023-10-01 |
| KR102799778B1 (ko) | 2025-04-28 |
| KR20250057946A (ko) | 2025-04-29 |
| AU2022203180A1 (en) | 2022-06-02 |
| JP2022037131A (ja) | 2022-03-08 |
| HK1250995A1 (zh) | 2019-01-18 |
| KR20170135885A (ko) | 2017-12-08 |
| NZ735659A (en) | 2023-08-25 |
| AU2016243160A1 (en) | 2017-10-05 |
| US20180298110A1 (en) | 2018-10-18 |
| AU2022203180B2 (en) | 2025-09-11 |
| IL254292A0 (en) | 2017-10-31 |
| JP2018514510A (ja) | 2018-06-07 |
| KR102607829B1 (ko) | 2023-12-01 |
| MX2023010206A (es) | 2023-09-11 |
| JP2023130442A (ja) | 2023-09-20 |
| JP7309836B2 (ja) | 2023-07-18 |
| CA2979713A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009404A2 (es) | Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
| BR112017006664A2 (pt) | terapias de combinação | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2017006653A (es) | Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| TR201819092T4 (tr) | Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler. | |
| IL259691A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX373965B (es) | Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| EA201890212A1 (ru) | Новое применение сульфата декстрана | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. |